Avaxia Biologics
Latest round
- Series B
Last raised
- Jun 2013
Total raised
- $13M
Investors
- 14
About Avaxia Biologics
Founded in 2005 and headquartered in Lexington, US, Avaxia Biologics specializes in antibody therapeutics for gastrointestinal conditions.Avaxia Biologics specializes in the development of gut-targeted antibody therapeutics, with its primary product being AVX-470, a bovine polyclonal milk-derived anti-TNF antibody. This innovative therapy has demonstrated efficacy in treating ulcerative colitis (UC), as evidenced by successful results from Phase 1b clinical trials. The company’s technology allows for the creation of GI-stable recombinant monoclonal antibodies known as Avaximabs™, targeted for inflammatory bowel disease (IBD) in both pediatric and adult populations.Avaxia Biologics generates revenue through strategic partnerships and agreements focused on commercializing its proprietary gut-targeted therapeutics. The company aims to license its technology to other entities, facilitating the distribution of its flagship product, AVX-470, and other Avaximabs™. These collaborations often involve revenue-sharing models or direct sales to healthcare providers specializing in IBD treatment. The company is focused on expanding into North America and Europe, where the demand for its therapies is substantial.
Who invested in Avaxia Biologics
14 investors across 3 rounds
See all investors in Avaxia Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Avaxia Biologics
Who invested in Avaxia Biologics?
Avaxia Biologics has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Avaxia Biologics raised?
Avaxia Biologics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Avaxia Biologics last raise money?
Avaxia Biologics's most recent round on record is a Series B, in Jun 2013.
What does Avaxia Biologics do?
Founded in 2005 and headquartered in Lexington, US, Avaxia Biologics specializes in antibody therapeutics for gastrointestinal conditions.
Where is Avaxia Biologics headquartered?
Avaxia Biologics is headquartered in Lexington, US.
Which VCs invest in companies like Avaxia Biologics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Avaxia Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Avaxia Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.